Novo Targets Teens With Wegovy As It Heads Off Lilly Mounjaro Threat

 
• By Ayisha Sharma

The Danish firm’s GLP-1 receptor agonist triggered significant weight loss in a Phase III trial in obese teenagers, sparking filing plans that could strengthen the product’s market share even as rival Eli Lilly mounts a threat with Mounjaro.  

Apple with measuring tape on blue background. Weight loss, counting calories and healthy eating concept
Obesity Costs The Us Healthcare System More Than $150bn Annually • Source: Shutterstock

More from Clinical Trials

More from R&D